We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $799M
1-Year Est. Return 253.51%
This Fund
S&P 500
This Quarter Est. Return
+15.27%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$878M
AUM Growth
-$262M
Cap. Flow
-$297M
Cap. Flow %
-33.85%
Top 10 Hldgs %
94.53%
Holding
27
New
2
Increased
–
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
XNCR icon
Xencor
XNCR
+$28.4M
2
NNOX icon
Nano X Imaging
NNOX
+$3.99M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$329M
2
NPCE icon
Neuropace
NPCE
+$879K
3
ZY
Zymergen Inc. Common Stock
ZY
+$218K

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Technology 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
1
Arrowhead Research
ARWR
$12.1B
$216M 24.61%
3,260,869
– –
FATE icon
2
Fate Therapeutics
FATE
$294M
$198M 22.51%
3,379,064
– –
PTGX icon
3
Protagonist Therapeutics
PTGX
$9.8B
$83.8M 9.54%
2,449,183
– –
LEGN icon
4
Legend Biotech
LEGN
$3.93B
$75.9M 8.64%
1,629,173
– –
HLTH
5
DELISTED
Cue Health Inc. Common Stock
HLTH
$74.4M 8.47%
5,548,864
– –
MGTX icon
6
MeiraGTx Holdings
MGTX
$1.17B
$68.8M 7.83%
2,898,550
– –
CVRX icon
7
CVRx
CVRX
$78.3M
$42.8M 4.87%
3,495,575
– –
XNCR icon
8
Xencor
XNCR
$1.71B
$30M 3.42%
+748,062
New +$28.4M
PRCT icon
9
Procept Biorobotics
PRCT
$1.26B
$25.5M 2.9%
1,018,478
– –
FUSN
10
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$15.3M 1.74%
3,670,516
– –
ACET icon
11
Adicet Bio
ACET
$77.3M
$12.7M 1.45%
45,559
– –
VOR icon
12
Vor Biopharma
VOR
$1.38B
$12.5M 1.42%
53,733
– –
PNT
13
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$5.6M 0.64%
1,000,000
– –
PHAS
14
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$4.19M 0.48%
1,607,044
– –
PHGE icon
15
BiomX
PHGE
$1.67M
$3.41M 0.39%
11,228
– –
SLGC
16
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$3.27M 0.37%
281,052
– –
NNOX icon
17
Nano X Imaging
NNOX
$73.2M
$2.8M 0.32%
+192,429
New +$3.99M
ALDX icon
18
Aldeyra Therapeutics
ALDX
$86.9M
$1.58M 0.18%
394,834
– –
CSLT
19
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$1.25M 0.14%
811,295
– –
TCON
20
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$233K 0.03%
4,200
– –
LUNG icon
21
Pulmonx
LUNG
$92.8M
$181K 0.02%
5,639
– –
SENS icon
22
Senseonics Holdings Inc
SENS
$409M
$146K 0.02%
2,731
– –
CALC icon
23
CalciMedica
CALC
$20.2M
$91K 0.01%
3,539
– –
GYRE icon
24
Gyre Therapeutics
GYRE
$693M
$61K 0.01%
8,927
– –
ILMN icon
25
Illumina
ILMN
$29.1B
– –
-832,855
Closed -$329M
1
2

Similar funds

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
UM
Ulysses Management New York $802M AUM 5.35% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return

Johnson & Johnson's Q4 2021 Portfolio in Review

As of Q4 2021, Johnson & Johnson held 27 positions worth $878M, down 23% from $1.14B the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Johnson & Johnson withdrew a net $297M in Q4 2021, closing 3 positions. Its most notable exit was Illumina, an estimated $329M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology.

Against the trend, Johnson & Johnson opened a new position in Xencor worth $30M.

  • Johnson & Johnson's largest Q4 2021 buy was Xencor: 748,062 shares worth $30M.
  • Johnson & Johnson fully exited Illumina in Q4 2021, selling an estimated $329M.
  • Johnson & Johnson's ten largest holdings make up 95% of its $878M portfolio in Q4 2021.
  • Johnson & Johnson opened 2 new positions and closed 3 in Q4 2021.
  • Johnson & Johnson's portfolio value fell 23% quarter-over-quarter to $878M.

Based on Johnson & Johnson's 13F filing for Q4 2021, filed 14 Feb 2022.